Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Decoy receptors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A decoy receptor is a receptor that is able to recognize and bind specific growth factors or cytokines efficiently, but is not structurally able to signal or activate the intended receptor complex. It acts as an inhibitor, binding a ligand and keeping it from binding to its regular receptor. Decoy receptors participate in a common methods of signal inhibition and are also abundant in malignant tissues, making up a significant topic in cancer research.
Compositions and methods of treating disease with FGFR fusion proteins
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
Owner:FIVE PRIME THERAPEUTICS
Soluble TNF receptors and their use in treatment of disease
The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
Owner:NORTH CAROLINA AT CHAPEL HILL THE UNIV OF +2
Compositions and Methods of Treating Disease with Fgfr Fusion Proteins
InactiveUS20080171689A1Less susceptible to cleavageSenses disorderPeptide/protein ingredientsCancer cellEphA Receptors
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
Owner:FIVE PRIME THERAPEUTICS
COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF lgG-DECOY RECEPTOR FUSION PROTEINS
Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition.
Owner:JCR PHARMA +1
Polypeptides that Bind TRAIL-R1 and TRAIL-R2
Owner:ANAPHORE INC
Method of treating eye disease using glycosylated VEGF decoy receptor fusion protein
ActiveUS20160024483A1Improved pharmacokinetic profileStrong and durable anti-angiogenicSenses disorderPeptide/protein ingredientsDecoy receptorsNucleotide
The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.
Owner:KOREA ADVANCED INST OF SCI & TECH +1
Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof
The invention provides monoclonal antibodies against decoy receptor 3 (DcR3), hybridomas producing said antibodies, kits containing said monoclonal antibodies and uses of the hybridomas, antibodies and kits for the detection of DcR3-associated diseases, as well as for the treatment and / or prevention of DcR3-associated diseases.
Owner:ANAWRAHTA BIOTECH
il-17rc-hfc fusion protein and its application
The invention provides fusion protein of a human interleukin receptor C (IL-17RC). The fusion protein contains a key region where the human IL-17RC is bonded with interleukin 17A(IL-17A) and interleukin 17F(IL-17F)and a human IgG1 Fc segment. The IL-17RC-hFc fusion protein provided by the invention has the capacity of binding the IL-17A and the IL-17F, can inhibit release of inflammatory cytokines and expression of RANKL molecules irritated by the IL-17A and the IL-17F, can be used for treating IL-17 associated autoimmune diseases such as rheumatoid arthritis and the like, and exerts the effects of inhibiting inflammation and antagonizing bone destruction. The IL-17RC-hFc fusion protein can serve as a therapeutic bait receptor and provides a new therapeutic approach and thought for diseases such as rheumatoid arthritis and the like. The IL-17RC-hFc fusion protein is subjected to prokaryotic expression in vitro; and the method is high in expression quantity, high in controllability, relatively low in production cost and easy in large-scale production.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Recombinant Adenovirus Having Anti-Angiogenesis Activity
InactiveUS20130101557A1Inhibit angiogenesisCancer treatment is limitedSenses disorderVirusesDiseaseNucleotide
The present disclosure relates to a recombinant adenovirus with improved angiogenesis inhibition activity and a pharmaceutical composition for inhibiting angiogenesis. The recombinant adenovirus includes: (a) an inverted terminal repeat (ITR) nucleotide sequence of an adenovirus; and (b) a nucleotide sequence coding for a chimeric decoy receptor containing (i) an extracellular domain of vascular endothelial growth factor receptor 1 (VEGFR-1) and (ii) an extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2). The recombinant adenovirus according the present disclosure which expresses the chimeric decoy receptor inhibits angiogenesis very effectively and can be used for gene therapy for various angiogenesis-related diseases. Particularly, the recombinant adenovirus of the present disclosure has superior oncolytic activity.
Owner:IUCF HYU (IND UNIV COOP FOUND HANYANG UNIV)
Tgf-ß decoy receptor
InactiveUS20190352373A1Reduce the overall heightRepress production of pro-apoptotic factorsImmunoglobulin superfamilyPeptide/protein ingredientsDecoy receptorsReceptor for activated C kinase 1
A TGF-β decoy receptor comprising a TGF-β binding region and a lipid anchor region is disclosed. Also disclosed is a chimeric antigen receptor (CAR) comprising a TGF-β binding region. Also disclosed are compositions comprising, and methods using, the TGF-β decoy receptors and CARs.
Owner:TESSA THERAPEUTICS PTE LTD
Preparation and use of OPG-HSP70 fusion protein
InactiveCN101434656AInhibition of bone destructionInhibit inflammationPeptide/protein ingredientsSkeletal disorderOsteoblastInflammatory arthropathy
The invention relates to 'a preparation method of OPG-HSP70 fusion protein and an application thereof', pertaining to the new technology field of biological medicaments. The preparation method provides an OPG-HSP70 fusion protein (osteoprotegerin-heat shock protein 70) medicament. According to the most significant pathological features of the rheumatoid arthritis (RA) i.e. the arthrosynovitis with cartilage and bone destruction, the medicament uses the osteoprotegerin as the decoy receptor to combine with the receptor activator of nuclear factor-kB ligand (RANKL) of the nuclear factor kB expressed by osteoblast and other cells, and to interrupt the combination between the RANKL and the RANK expressed by the osteoclast so as to inhibit the bone resorption involved by the osteoclast; and the medicament uses the protective polypeptide segments of the heat shock protein (HSP) to inhibit the inflammatory arthritis. The method contains the DNA sequence which encodes the fusion protein, the method for generating the fusing protein by the recombinant technology, the biological activity of the fusion protein and the like.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Methods of Treating Autoimmune Conditions in Patients with Genetic Variations in DCR3 or in a DCR3 Network Gene
ActiveUS20170051352A1Improve cell activityIncreased production of IFN-gammaNervous disorderAntipyreticAutoimmune conditionIsrapafant
The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Glycosylated VEGF decoy receptor fusion protein
ActiveUS20160032259A1Potent activityLimited clinical efficacySenses disorderBacteriaDecoy receptorsNucleotide
The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.
Owner:KOREA ADVANCED INST OF SCI & TECH
Method of Preventing or Reducing Virus Transmission in Animals
The subject invention provides materials and methods for improving animal resistance to infection by intestinal viruses. This is accomplished by interfering with intestinal virus uptake employing methods that (1) reduce virus binding to receptors in the intestinal lining; (2) introduce decoy receptors expressed in the mammary gland leading to decoy secretion in milk; (3) produce decoy receptors by a variety of protein synthesis methods to provide decoy receptors to non-genetically modified animals, including humans; and / or (4) administer a vector to a non-genetically modified animal which vector has been genetically modified to produce a decoy receptor.
Owner:AGGENETICS
Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition.
Owner:JCR PHARMA +1
Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene
ActiveUS10407725B2Improve cell activityIncrease productionNervous disorderAntipyreticAutoimmune conditionIsrapafant
The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
TGF-beta decoy receptor
InactiveCN110709416AImmunoglobulin superfamilyPeptide/protein ingredientsDecoy receptorsAntigen receptors
A TGF-beta decoy receptor comprising a TGF-beta binding region and a lipid anchor region is disclosed. Also disclosed is a chimeric antigen receptor (CAR) comprising a TGF-beta binding region. Also disclosed are compositions comprising, and methods using, the TGF-beta decoy receptors and CARs.
Owner:特沙公司
Conjugate of VEGF-GRAB protein and drug, and use thereof
PendingCN111032092AAntibody mimetics/scaffoldsImmunoglobulins against growth factorsDiseaseDecoy receptors
Owner:KOREA ADVANCED INST OF SCI & TECH
Methods of treating metastatic cancers using axl decoy receptors
PendingUS20200289613A1High indexCombination is synergisticOrganic active ingredientsCell receptors/surface-antigens/surface-determinantsDecoy receptorsPharmaceutical drug
Compositions and methods are provided for treating a human metastatic cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:ARAVIVE BIOLOGICS INC
Preparation method and application of osteoporotegerin-heat-shock protein 65-fused protein
InactiveCN101812474AInhibition of bone destructionInhibit inflammationMicroorganism based processesSkeletal disorderOsteoblastSYNOVIAL SWELLING
The invention relates to a preparation method and application of an osteoporotegerin-heat-shock protein 65-fused protein, belonging to the new technical field of biomedicine. The invention provides an osteoporotegerin-heat-shock protein 65 (OPG-HSP 65)-fused recombinant protein medicament. Aiming at the most important pathological feature of rheumatoid arthritis (RA) that articular synovitis is accompanied with the destroy of cartilages and bones, the medicament can be combined with a receptor activator of nuclear factor kappa B ligand (RANKL) expressed by cells comprising osteoblasts and the like through using osteoporotegerin (OPG) as a decoy receptor to block the combination of the RANKL and a RANK (Receptor Activator of NF-kB) expressed by osteoclasts, thereby inhibiting the bone absorption that the osteoclasts participate; and the medicament inhibits articular inflammations by utilizing the protective polypeptide segment of the heat-shock protein (HSP). The invention comprises a DNA (Deoxyribonucleic Acid) sequence for encoding recombinant protein, a method for generating the recombinant protein through a recomposition technique, the biologic activity of the recombinant protein and the like.
Owner:李慎涛 +2
Mutants of highly active tumor necrosis factor-related apoptosis-inducing ligands
The invention belongs to the field of biological pharmacy and particularly relates to a mutant of a TRAIL (TNF (tumor necrosis factor)-related apoptosis-inducing ligand) and a pharmaceutical application of the mutant. Due to the fact that a wild type TRAIL can be simultaneously combined with tumor cell membrane surface DR (death receptor)4 and DR5 as well as a DcR (decoy receptor)1 and a DcR2 and can be combined with a soluble receptor OPG (osteoprotegrin) by the aid of very low affinity, but tumor cell apoptosis can be induced only through combination of the wild type TRAIL with the DR4 and the DR5; in order to enhance the anti-tumor activity of the TRAIL, the TRAIL mutant having high affinity with the DR5 is designed and constructed, and the TRAIL mutant is characterized by containing E263G mutation, that is, the 263th Glu is mutated into Gly. SEC-HPLC (size exclusion chromatography-high performance liquid chromatography) analysis indicates that the mutant exists in a form of a tripolymer with activity after the mutant is subjected to soluble expression and purification in E.coli. The affinity of the mutant with the DR5 is remarkably improved, and the anti-tumor activity of the mutant is further remarkably improved.
Owner:CHINA PHARM UNIV
Conjugate of vegf-grab protein and drug, and use thereof
PendingUS20200148757A1Efficient selectionInhibit growthAntibody mimetics/scaffoldsImmunoglobulins against growth factorsDiseaseDecoy receptors
The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a drug, a pharmaceutical composition for prevention or treatment of cancer or angiogenesis-related disease, comprising the conjugate, and a method for prevention or treatment of cancer or angiogenesis-related disease. Serving as a multi-paratopic VEGF decoy receptor, the conjugate including a VEGF-Grab protein and a drug of the present invention can be used as a multi-purpose platform for treatment of cancer or angiogenesis-related disease.
Owner:KOREA ADVANCED INST OF SCI & TECH
Soluble TNF receptors and their use in treatment of disease
Owner:SANTARIS PHARMA AS +2
Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
ActiveUS20200164032A1Avoid accumulationPeptide/protein ingredientsPeptidesDecoy receptorsCell biology
The present disclosure generally provides compositions and methods related to the field of immunology. Specifically, disclosed herein are chemokine binding proteins and methods of use thereof.
Owner:WASHINGTON UNIV IN SAINT LOUIS
Anti-cancer compositions containing WNT decoy receptor
ActiveUS9657069B2Inhibition of activationMaximized inhibitory activityOrganic active ingredientsPeptide/protein ingredientsLymphatic SpreadCancer cell
The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.
Owner:GENEMEDICINE CO LTD
IL-17RC-hFc fusion protein and application thereof
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Preparation method and application of opg-hsp70 fusion protein
InactiveCN101434656BInhibition of bone destructionInhibit inflammationPeptide/protein ingredientsSkeletal disorderJoints inflammationA-DNA
The invention is a "preparation method and application of OPG-HSP70 fusion protein", which belongs to the field of biomedical new technology. The invention provides an osteoprotegerin-heat shock protein 70 (OPG-HSP70) fusion protein drug. The drug targets synovitis, the most important pathological feature of rheumatoid arthritis (RA), accompanied by destruction of cartilage and bone. Through osteoprotegerin (OPG) as a decoy receptor, it can interact with cells expressed by osteoblasts and other cells. Receptor Activator of Nuclear Factor κB Ligand (RANKL) binds, blocks the binding of RANKL to RANK expressed by osteoclasts, thereby inhibiting bone resorption involving osteoclasts; uses the protective polypeptide fragment of heat shock protein (HSP) to inhibit joint inflammation. The invention includes the DNA sequence encoding the fusion protein; the method of producing the fusion protein through recombinant technology; and the biological activity of the fusion protein, etc.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration
ActiveUS20190017095A1Balanced therapeutic profile of efficacyReduce adverse reactionsBiocideSugar derivativesDiseaseCell adhesion
Owner:TUMOREND
Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration
Owner:TUMOREND
Soluble TNF receptors and their use in treatment of disease
The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
Owner:NORTH CAROLINA AT CHAPEL HILL THE UNIV OF +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com